Volume 5, Issue 8.
In this podcast, Andrew J. Muir, MD from Duke University School of Medicine discusses the real-world data to support a sofosbuvir-ledipasvir treatment duration of 8 weeks versus 12 weeks, summarizes the current hepatitis C treatment options for patients with advanced kidney disease, and describes the risks and benefits of hepatitis C therapies in HIV-HCV coinfected patients.
Take our post-test to claim CME credits:
To read a companion newsletter click here.
Podcast (eviralhepatitis): Play in new window | Download
Subscribe: Apple Podcasts | Android | RSS